Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
| Autor: | Daniel Guy, Geoffrey L. Uy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty T cell CD33 Article 03 medical and health sciences Internal medicine hemic and lymphatic diseases Antibodies Bispecific Medicine Humans Receptor neoplasms Hematology biology business.industry Myeloid leukemia Cancer medicine.disease Leukemia Myeloid Acute 030104 developmental biology medicine.anatomical_structure Oncology biology.protein Cancer research Interleukin-3 receptor Antibody business |
| Popis: | PURPOSE OF REVIEW: Bispecific antibodies combine antigen recognition sites from two or more antibodies into a single construct allowing simultaneous binding to multiple targets. Bispecific antibodies exist which can redirect immune effector cells against AML targets. This review will highlight the progress to date and the challenges in developing bispecific antibodies for the treatment of acute myeloid leukemia (AML). RECENT FINDINGS: Currently, a number of bispecific antibodies formats including bispecific T cell engagers, dual affinity retargeting proteins, and tandem diabodies are in clinical development for AML. These antibodies target antigens present on AML blasts including CD33, and the low affinity IL3 receptor, CD123. T-cell redirecting bispecific antibodies in early phase clinical trials for AML include AG330, flotetuzumab, JNJ-63709178 and AMV564. SUMMARY: Bispecific antibodies represent a promising immunotherapeutic approach for the treatment of cancer. The results of ongoing studies in AML will elucidate the potential for these agents in AML |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|